脑肿瘤诊断市场：按测试类型、脑肿瘤类型划分 - 全球预测 2023-2030

全球脑肿瘤诊断市场预计将以 12.42% 的复合年增长率大幅成长，到 2023 年达到 40.2343 亿美元，2030 年达到 91.434 亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球脑肿瘤诊断市场至关重要。透过检验业务策略和产品满意度等关键指标，它可以对供应商进行全面评估，使用户能够根据自己的特定需求做出资讯的决策。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.脑肿瘤诊断的全球市场规模与预测为何？

2.在预测期内，COVID-19 对全球脑肿瘤诊断市场的阻碍因素和影响为何？

3.在预测期内，全球脑瘤诊断市场需要投资哪些产品/细分市场/应用/领域？

4.你们在全球脑瘤诊断市场的竞争策略是什么？

5.全球脑肿瘤诊断市场的技术趋势和法律规范是什么？

6.全球脑肿瘤诊断市场主要厂商的市占率为何？

7. 哪些型态和策略措施被认为适合进入全球脑肿瘤诊断市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 脑肿瘤发生率增加
    • 私人诊断中心和公私伙伴关係数量的增加
  • 抑制因素
    • 诊断费用高，诊断意识低
  • 机会
    • 诊断设备的技术进步
    • 开发各种癌症突变的诊断方法
  • 任务
    • 高辐射暴露风险增加和严格的法规指南
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章按测试类型分類的脑肿瘤诊断市场

• 磁振造影
• 磁共振波谱
• 正子断层扫描
• 脊椎穿刺

第7章以脑肿瘤类型分類的脑肿瘤诊断药物市场

• 听神经瘤
• 星状细胞瘤
• 脊索瘤
• 室管膜瘤

第8章北美和南美脑肿瘤诊断市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第9章亚太脑肿瘤诊断市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第10章欧洲、中东和非洲脑肿瘤诊断市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第11章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

• 讨论指南
• 关于许可证和定价

The Global Brain Cancer Diagnostics Market is forecasted to grow significantly, with a projected USD 4,023.43 million in 2023 at a CAGR of 12.42% and expected to reach a staggering USD 9,143.40 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Brain Cancer Diagnostics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Brain Cancer Diagnostics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Test Type, market is studied across Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, PET Scan, and Spinal Tap. The PET Scan is projected to witness significant market share during forecast period.

Based on Brain Cancer Type, market is studied across Acoustic Neuroma, Astrocytomas, Chordomas, and Ependymomas. The Ependymomas is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Brain Cancer Diagnostics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Brain Cancer Diagnostics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Brain Cancer Diagnostics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Brain Cancer Diagnostics Market?

4. What is the competitive strategic window for opportunities in the Global Brain Cancer Diagnostics Market?

5. What are the technology trends and regulatory frameworks in the Global Brain Cancer Diagnostics Market?

6. What is the market share of the leading vendors in the Global Brain Cancer Diagnostics Market?

7. What modes and strategic moves are considered suitable for entering the Global Brain Cancer Diagnostics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Brain Cancer Diagnostics Market, by Test Type, 2022 vs 2030
• 4.3. Brain Cancer Diagnostics Market, by Brain Cancer Type, 2022 vs 2030
• 4.4. Brain Cancer Diagnostics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of brain cancer
    • 5.1.1.2. Growth in the number of private diagnostic centers and rising public-private partnerships
  • 5.1.2. Restraints
    • 5.1.2.1. Heavy costs associated with diagnosis and low awareness about the diagnosis
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancement in diagnostics devices
    • 5.1.3.2. Development of diagnostic approaches for various cancer mutations
  • 5.1.4. Challenges
    • 5.1.4.1. Rising risk of high radiation exposure and stringent regulatory guidelines
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Brain Cancer Diagnostics Market, by Test Type

• 6.1. Introduction
• 6.2. Magnetic Resonance Imaging
• 6.3. Magnetic Resonance Spectroscopy
• 6.4. PET Scan
• 6.5. Spinal Tap

7. Brain Cancer Diagnostics Market, by Brain Cancer Type

• 7.1. Introduction
• 7.2. Acoustic Neuroma
• 7.3. Astrocytomas
• 7.4. Chordomas
• 7.5. Ependymomas

8. Americas Brain Cancer Diagnostics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Brain Cancer Diagnostics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Brain Cancer Diagnostics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. BRAIN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2022 VS 2030 (%)
• FIGURE 5. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2022 VS 2030 (%)
• FIGURE 6. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. BRAIN CANCER DIAGNOSTICS MARKET DYNAMICS
• FIGURE 8. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. BRAIN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 5. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SPINAL TAP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 10. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CHORDOMAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EPENDYMOMAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 21. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 22. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 33. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 35. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 36. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 71. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 78. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 79. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 80. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 81. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 100. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 101. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 102. BRAIN CANCER DIAGNOSTICS MARKET LICENSE & PRICING